Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Nivolumab Plus Lenvatinib for Patients With Unresectable Anaplastic Thyroid Cancer (NAVIGATION Study)

NCT05696548 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT05696548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05696548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Nivolumab Plus Lenvatinib for Patients With Unresectable Anaplastic Thyroid Cancer (NAVIGATION Study)
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 2, 2019
Completion date
December 31, 2026
Enrollment
51 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic thyroid cancer